Could a single blood test speed up HAE diagnosis?
NCT ID NCT07293364
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether measuring just one protein function (C1-inhibitor) can accurately diagnose hereditary angioedema (HAE), a rare condition causing sudden swelling. About 514 people in Algeria who are suspected of having HAE or have family members with it will take part. Researchers will compare the new single-test method to the standard battery of tests to see if it works just as well.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA (HAE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
EPH de Rouiba (Etablissement Public Hospitalier)
RECRUITINGAlgiers, 16017, Algeria
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- HAE patients and caregivers speak out: the hidden costs of On-Demand treatment
- Real-world study shows lanadelumab keeps HAE attacks at bay for many patients
- Takhzyro under the microscope: Real-World safety check for rare swelling disease
- New hope for HAE patients: experimental drug aims to slash attack rate
- New RNA drug shows promise in preventing HAE attacks in ongoing study
- New drug TAKHZYRO tracked for Long-Term safety in rare swelling disorder